Daniel M. Weinberger

Daniel M. Weinberger

Auto-generated profile, based on publicly available information

Daniel M. Weinberger

Department of Epidemiology of Microbial Diseases, Yale School of Public Health; New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in The Lancet
Verified
Journal Article
Closed access
DWDaniel M Weinberger
Daniel M Weinberger
RMRichard Malley
Richard Malley
MLMarc Lipsitch
Marc Lipsitch

1 October 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
DWDaniel M. Weinberger
Daniel M. Weinberger
JCJenny Chen
Jenny Chen
TCTed Cohen
Ted Cohen
FCForrest W. Crawford
Forrest W. Crawford
FMFarzad Mostashari
Farzad Mostashari
CVCecile Viboud
Cecile Viboud
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in December 2019 in Wuhan, China, and rapidly grew into a global pandemic.1 Without adequate capacity to test for SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), during the early part of the pandemic, laboratory-confirmed cases captured only an estimated 10% to 15% of all infections.2 As a result, estimating the number of deaths caused by COVID-19 is a challenge.

27 February 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MAMarina Antillón
Marina Antillón
JWJoshua L. Warren
Joshua L. Warren
FCForrest W. Crawford
Forrest W. Crawford
DWDaniel M. Weinberger
Daniel M. Weinberger
EKEsra Kürüm
Esra Kürüm
VPVirginia E. Pitzer
Virginia E. Pitzer
Upcoming vaccination efforts against typhoid fever require an assessment of the baseline burden of disease in countries at risk. There are no typhoid incidence data from most low- and middle-income countries (LMICs), so model-based estimates offer insights for decision-makers in the absence of readily available data. We developed a mixed-effects model fit to data from 32 population-based studies of typhoid incidence in 22 locations in 14 countries. We tested the contribution of economic and environmental indices for predicting typhoid incidence using a stochastic search variable selection algorithm. We performed out-of-sample validation to assess the predictive performance of the model. We estimated that 17.8 million cases of typhoid fever occur each year in LMICs (95% credible interval: 6.9–48.4 million). Central Africa was predicted to experience the highest incidence of typhoid, followed by select countries in Central, South, and Southeast Asia. Incidence typically peaked in the 2–4 year old age group. Models incorporating widely available economic and environmental indicators were found to describe incidence better than null models. Recent estimates of typhoid burden may under-estimate the number of cases and magnitude of uncertainty in typhoid incidence. Our analysis permits prediction of overall as well as age-specific incidence of typhoid fever in LMICs, and incorporates uncertainty around the model structure and estimates of the predictors. Future studies are needed to further validate and refine model predictions and better understand year-to-year variation in cases. Typhoid fever is a bacterial enteric infection that continues to pose a considerable burden to the 5.5 billion people living in low- and middle-income countries (LMICs). We developed and validated a model incorporating widely available indicators of economic and social development and the environment to estimate the burden of typhoid fever across LMICs. Our analysis uses all available data to estimate the incidence of typhoid in key age groups, which is important for the design and implementation of optimal vaccination strategies, and it identifies regions of the world that have the most uncertainty in typhoid incidence. Across all LMICs, we estimated that the expected number of typhoid fever cases per year is 17.8 million (95% CI: 6.9–48.4 million). We also present the probability that incidence surpasses the criteria for low, medium, high, and very high incidence in each country, which could help guide policy in the face of uncertainty.

15 September 2010 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DWDaniel M. Weinberger
Daniel M. Weinberger
Zitta F B Barrella HarboeZitta F B Barrella Harboe
Zitta F B Barrella Harboe
ESElisabeth A. M. Sanders
Elisabeth A. M. Sanders
MNMoses Ndiritu
Moses Ndiritu
KKKeith P. Klugman
Keith P. Klugman
MLMarc Lipsitch
Marc Lipsitch
Background. The 92 capsular serotypes of Streptococcus pneumoniae differ greatly in nasopharyngeal carriage prevalence, invasiveness, and disease inc

16 July 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
Zitta F B Barrella HarboeZitta F B Barrella Harboe
Zitta F B Barrella Harboe
Tine DalbyTine Dalby
Tine Dalby
DWDaniel M. Weinberger
Daniel M. Weinberger
TBThomas Benfield
Thomas Benfield
KMKåre Mølbak
Kåre Mølbak
PVPalle Valentiner-Branth
Palle Valentiner-Branth
Background. The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population level is unclear. We explored PCV13's effect in reducing invasive pneumococcal disease (IPD)–related morbidity and mortality, and whether serotype-specific changes were attributable to vaccination or expected as a part of natural, cyclical variations. Methods. This was a Danish nationwide population-based cohort study based on the linkage of laboratory surveillance data and the Danish Civil Registration System. Changes in IPD incidence and mortality during baseline (2000–2007), 7-valent pneumococcal conjugate vaccine (PCV7) (2008–2010), and PCV13 (2011–2013) periods were estimated. Predicted incidences of serotypes were estimated controlling for cyclical trends from historical patterns observed during the past 20 years. Results. We observed a 21% reduction (95% confidence interval [CI], 17%–25%) in IPD incidence in the total population after PCV13's introduction, and a 71% reduction (95% CI, 62%–79%) in children aged <2 years, considered as the vaccine effectiveness. We estimated a 28% reduction (95% CI, 18%–37%) in IPD-related 30-day mortality, from 3.4 deaths (95% CI, 3.2–3.6) per 100 000 population in the pre-PCV period to 2.4 (95% CI, 2.2–2.7) in the PCV13 period. The decline in mortality was observed across all age groups but was mainly related to mortality reductions in the nonvaccinated population. For serotypes 1 and 3, there were no significant changes in incidence beyond what would be expected from natural cyclical patterns. Serotype 19A significantly increased following PCV7's introduction, but the incidence declined toward baseline in 2012. Conclusions. PCV13 has brought greater benefits than we had expected in our setting. We observed a further decline on IPD incidence shortly after the shift from PCV7 to PCV13 in the national immunization program. This decline was accompanied by a substantial population-level decline in pneumococcal-related mortality of nearly 30% among nonvaccinated persons.

12 June 2009 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DWDaniel M. Weinberger
Daniel M. Weinberger
KTKrzysztof Trzcinski
Krzysztof Trzcinski
YLYing-Jie Lu
Ying-Jie Lu
DBDebby Bogaert
Debby Bogaert
ABAaron Brandes
Aaron Brandes
MLMarc Lipsitch
Marc Lipsitch
There are 91 known capsular serotypes of Streptococcus pneumoniae. The nasopharyngeal carriage prevalence of particular serotypes is relatively stable worldwide, but the host and bacterial factors that maintain these patterns are poorly understood. Given the possibility of serotype replacement following vaccination against seven clinically important serotypes, it is increasingly important to understand these factors. We hypothesized that the biochemical structure of the capsular polysaccharides could influence the degree of encapsulation of different serotypes, their susceptibility to killing by neutrophils, and ultimately their success during nasopharyngeal carriage. We sought to measure biological differences among capsular serotypes that may account for epidemiological patterns. Using an in vitro assay with both isogenic capsule-switch variants and clinical carriage isolates, we found an association between increased carriage prevalence and resistance to non-opsonic neutrophil-mediated killing, and serotypes that were resistant to neutrophil-mediated killing tended to be more heavily encapsulated, as determined by FITC-dextran exclusion. Next, we identified a link between polysaccharide structure and carriage prevalence. Significantly, non-vaccine serotypes that have become common in vaccinated populations tend to be those with fewer carbons per repeat unit and low energy expended per repeat unit, suggesting a novel biological principle to explain patterns of serotype replacement. More prevalent serotypes are more heavily encapsulated and more resistant to neutrophil-mediated killing, and these phenotypes are associated with the structure of the capsular polysaccharide, suggesting a direct relationship between polysaccharide biochemistry and the success of a serotype during nasopharyngeal carriage and potentially providing a method for predicting serotype replacement. Streptococcus pneumoniae, or pneumococcus, is an important pathogen worldwide and causes a wide range of diseases, mostly in young children and the elderly. There are 91 serotypes of pneumococcus, each of which produces a unique polysaccharide, called the capsule, that attaches to the bacterial surface and prevents it from being cleared by the host. The serotypes differ greatly in their prevalence in the human population. There is currently a vaccine, effective in infancy, which targets seven clinically important serotypes, but several types not covered by the vaccine are beginning to increase in carriage frequency. As a result, it is critical to understand why some serotypes are frequently carried in the human population while others are not. In this study, we find that the high-prevalence serotypes tend to be more heavily encapsulated and more resistant to killing by neutrophils. Significantly, we find that the biochemical properties of the different polysaccharides can be used to predict their carriage frequency both before and after introduction of the vaccine. These results provide a biologically plausible explanation for differences in prevalence between serotypes.